BioNTech's head and neck cancer vaccine fails to meet first primary endpoint in pivotal trial

BioNTech reported that its experimental mRNA vaccine targeting head and neck cancer did not achieve one of the two primary goals in a pivotal study.

The trial was designed to evaluate the vaccine’s ability to improve a specific clinical outcome, and the data showed that the first endpoint was not met.

This setback adds to the challenges the company faces with its mRNA oncology program, which has encountered several hurdles in recent years.

BioNTech will need to assess the results and determine next steps for the vaccine’s development, while investors watch the impact on the broader pipeline.